Mapping Quality of Life (EQ-5D) from DAPsA, Clinical DAPsA and HAQ in Psoriatic Arthritis

Mlcoch, T.; Tužil, Jan; Šedová, Liliana; Štolfa, Jiří; Urbanová, Marie; Suchý, David; Smrzova, Andrea; Jirčíková, Jitka; Hrnčiarová, Tereza; Pavelka, Karel; Doležal, Tomáš

doi:10.1007/s40271-017-0285-1

Cited by 9 publications

(13 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Disease status and functional status were strongly associated with EQ‐5D‐5L in each domain and HU in univariable analysis. This was consistent with previous reports . There are a variety of disease assessments for PsA.…”

Section: Discussionsupporting

confidence: 93%

“…In the multivariable regression analysis of the present study, two disease activity indices (cDAPSA and DAPSA) and HAQ were significantly associated with HU after adjusting for age. In the present study, DAPSA and cDAPSA were almost equally associated with HU, similar to Mlcoch’s study in the Czech Republic . Evaluation of acute phase response protein is an objective measure of inflammation and significantly associated with progression of damage in PsA .…”

Section: Discussionsupporting

confidence: 90%

“…This suggests that MDA could be an alternative aim of treatment choice if remission cannot be achieved . HAQ and disease activity indices of cDAPSA, DAPSA, or MDA were comparably associated with HU and explained approximately 63%‐65% of the variance in HU in our study, comparable to Mlcoch’s study . Some of the unexplained variance in HU may be due to other factors determining QoL, namely adaptation and environmental factors.…”

Section: Discussionsupporting

confidence: 82%

“…Therefore, we contend that cDAPSA could be used instead of DAPSA to estimate disease activity in PsA. Interestingly, functional index estimated by HAQ had a stronger association (ie, a higher standardized regression coefficient) with HU than disease activity index, similar to Mlcoch’s study . HAQ had a stronger negative correlation with HU ( r s −0.8) than cDAPSA ( r s −0.7) and DAPSA ( r s −0.6).…”

Section: Discussionsupporting

confidence: 68%

“…Psoriatic arthritis (PsA) is a chronic heterogeneous inflammatory rheumatic disease involving peripheral arthritis, enthesitis, sacroiliitis, spondylitis, and extra‐articular manifestations, mainly psoriasis (Ps). The course of PsA varies from mild to severely damaged joints, causing physical and functional impairment, and diminished quality of life (QoL) . The goal of treatment is achieving a good QoL by controlling inflammation, reducing symptoms, and maintaining musculoskeletal function …”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Disease activity and functional status associated with health‐related quality of life and patient‐acceptable symptom state in patients with psoriatic arthritis in Thailand: A cross‐sectional study

et al. 2019

View full text Add to dashboard Cite

Aim:To identify factors associated with the EuroQol-5 Dimensions-5 levels (EQ-5D-5L) and patient acceptable symptom state (PASS) and to estimate health utility (HU) in Thai patients with psoriatic arthritis (PsA). Methods:A cross-sectional study of consecutive PsA patients visiting Siriraj Hospital was performed between 31 May, 2012 and 31 March, 2016. Data of patient demographics, HU outcomes (Thai EQ-5D-5L), disease activity (Disease Activity Index for Psoriatic Arthritis [DAPSA], the Clinical DAPSA [cDAPSA], the minimal disease activity [MDA]), and the Health Assessment Questionnaire (HAQ) were collected.Regression analyses were used to explore factors associated with each EQ-5D domain, HU, and PASS. Results:Of 129 PsA patients, the mean age was 47.6 years; 53.5% were male. The mean HU was 0.76. Univariable analysis showed lower disease activity and less impaired function were significantly associated with higher HU and no to mild problem in each EQ-5D domain. Multivariable analysis showed HAQ and disease activity indices (cDAPSA, DAPSA, MDA) adjusting for age, had good goodness-of-fit to HU (adjusted R 2 : 0.63-0.65). Patients answering "yes" to PASS had significantly longer disease duration of PsA, higher HU, lower disease activity, less disability, and were more often married than those answering "no" to PASS. Pain problem was the most important association to PASS adjusting for other domains and age. Conclusions:Disease activity and functional status in PsA patients were significant factors related to HU and PASS. To improve quality of life, the goal of treatment should be achieving remission, improving function, and controlling pain. K E Y W O R D ScDAPSA, EQ-5D-5L, MDA, PASS, psoriatic arthritis | 701 CHIOWCHANWISAWAKIT eT Al.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 82%

Section: Discussionsupporting

confidence: 68%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Disease activity and functional status associated with health‐related quality of life and patient‐acceptable symptom state in patients with psoriatic arthritis in Thailand: A cross‐sectional study

et al. 2019

View full text Add to dashboard Cite

show abstract

Association Between Achievement of Clinical Disease Control and Improvement in Patient‐Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 SELECT‐PsA 1 and 2 Randomized Controlled Trials

Kavanaugh,

Mease,

Gossec

et al. 2024

ACR Open Rheumatology

View full text Add to dashboard Cite

ObjectiveWe explored the relationship between achievement of clinical disease control and improvements in and normative values for patient‐reported outcomes (PROs), including quality of life (QoL) measures, in patients with psoriatic arthritis (PsA).MethodsThis was a post hoc analysis of 104‐week data from the SELECT‐PsA 1 and 2 trials in adults with PsA and inadequate response to one or more conventional synthetic (SELECT‐PsA 1) or biologic (SELECT‐PsA 2) disease‐modifying antirheumatic drug. Patients were initially randomized to upadacitinib 15 mg once daily (QD) to placebo switched to upadacitinib 15 mg QD at week 24 or to adalimumab 40 mg every other week (SELECT‐PsA 1 only), and data were pooled across treatments and analyzed. We evaluated several clinical disease control measures (minimal disease activity [MDA]; very low disease activity [VLDA]; and low disease activity [LDA] and/or remission by Disease Activity in Psoriatic Arthritis [DAPSA], Psoriatic Arthritis Disease Activity Score [PASDAS], and Routine Assessment of Patient Index Data 3 [RAPID3]) and examined their associations with improvements and normative values for various PROs.ResultsA total of 1,069 and 317 patients were analyzed for SELECT‐PsA 1 and 2, respectively. In both studies, responders (patients who achieved MDA or VLDA, and DAPSA, PASDAS, and RAPID3 LDA or remission) at week 104 achieved more marked changes from baseline, and more responders achieved normative values in PROs compared with nonresponders (most nominal P < 0.0001). Furthermore, numerically larger proportions of responders achieved minimal clinically important differences across PROs compared with nonresponders in both studies. In addition, patients who achieved MDA or VLDA were more likely to achieve DAPSA, PASDAS, and RAPID3 LDA or remission (all nominal P < 0.0001) for upadacitinib 15 mg QD and when treatment arms were pooled.ConclusionPatients with PsA who achieve clinical disease control are more likely to achieve improvements and normative values in PROs and QoL measures, which reinforces disease control as a treatment target.

show abstract

An Updated Systematic Review of Studies Mapping (or Cross-Walking) Measures of Health-Related Quality of Life to Generic Preference-Based Measures to Generate Utility Values

Mukuria

Rowen

Harnan

et al. 2019

Appl Health Econ Health Policy

103

View full text Add to dashboard Cite

Short Running Title: Updated systematic review of studies mapping to preference-based measures Key points for decision-makers  Mapping or cross-walking enables utility values to be generated from other health related quality of life measures in studies where the preferred preference-based measure has not been used  This updated review shows that compared to 10 years ago, there are now many mapping functions (n=233 across 180 published studies) which can be used to generate utility values from a large number of measures with the majority being to EQ-5D-3L  Mapping studies now report important information that enable decision-makers to better understand and interpret mapped utility estimates, but mapping remains a second-best alternative to using the preference-based measures directly

show abstract

Mapping Quality of Life (EQ-5D) from DAPsA, Clinical DAPsA and HAQ in Psoriatic Arthritis

Abstract: This is the first mapping study conducted in PsA and we hope that our study will encourage further mapping studies in PsA. The results showed that in cases where CRP is absent, cDAPsA provides similar results to DAPsA in predicting QoL.

Cited by 9 publications

References 36 publications

Disease activity and functional status associated with health‐related quality of life and patient‐acceptable symptom state in patients with psoriatic arthritis in Thailand: A cross‐sectional study

Disease activity and functional status associated with health‐related quality of life and patient‐acceptable symptom state in patients with psoriatic arthritis in Thailand: A cross‐sectional study

Association Between Achievement of Clinical Disease Control and Improvement in Patient‐Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 SELECT‐PsA 1 and 2 Randomized Controlled Trials

An Updated Systematic Review of Studies Mapping (or Cross-Walking) Measures of Health-Related Quality of Life to Generic Preference-Based Measures to Generate Utility Values

Contact Info

Product

Resources

About